Dr. Yi-Long Wu
MD, FACS, Professor of Oncology
Chief Expert, Guangdong Provincial People's Hospital
corporate_fareGuangdong Provincial People's Hospital, Guangzhou
Yi-Long Wu
MD, FACS, Professor of Oncology
Prof. Yi-Long Wu is an internationally recognised thoracic oncologist and one of the leading figures in lung cancer precision medicine in China. He serves as Chief Expert at Guangdong Provincial People's Hospital and Honorary Director of the Guangdong Lung Cancer Institute in Guangzhou.
Over a career spanning nearly four decades, Prof. Wu has helped establish molecularly guided treatment as a standard approach for non-small cell lung cancer, particularly cancers driven by EGFR, ALK and ROS1 alterations. He founded the Chinese Thoracic Oncology Group (CTONG) in 2007 and has served as Principal Investigator or Co-Principal Investigator in more than 50 multicentre clinical trials. He was a co-author and investigator in the landmark IPASS trial, which helped establish EGFR mutation testing and first-line targeted therapy for advanced lung cancer. He also directs the Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, where his work focuses on turning molecular discoveries into practical treatment strategies that improve survival and quality of life for patients.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Wu, subject to hospital availability and case acceptance.
Why Consider Prof. Yi-Long Wu?
Prof. Wu combines decades of clinical experience with a research record that has helped shape how lung cancer is treated in China and internationally.
Areas of Specialization
Molecularly guided treatment for lung cancer
Prof. Wu focuses on selecting treatment based on the molecular characteristics of each tumour, with particular expertise in cancers driven by EGFR, ALK and ROS1 alterations.
EGFR-Mutated Lung Cancer
Targeted treatment selection for EGFR-driven non-small cell lung cancer.
- arrow_rightEGFR TKI selection (osimertinib, gefitinib, dacomitinib) for suitable patients
- arrow_rightTreatment planning guided by molecular testing
- arrow_rightManagement of T790M and other resistance after EGFR-targeted therapy
- arrow_rightRe-biopsy and repeat molecular profiling where appropriate
ALK and ROS1-Positive Lung Cancer
Targeted therapy for ALK and ROS1-rearranged lung cancer.
- arrow_rightALK inhibitors for ALK-positive disease
- arrow_rightROS1-directed treatment for suitable patients
Multidisciplinary and Adjuvant Care
Combined treatment planning across surgery, radiotherapy and systemic therapy.
- arrow_rightAdjuvant treatment after surgery for early-stage EGFR-mutated NSCLC
- arrow_rightPersonalised follow-up planning
- arrow_rightTreatment planning for unresectable Stage III NSCLC
- arrow_rightManagement of lung cancer with brain metastases
Clinical Services and Treatment Approaches
Precision oncology and multidisciplinary lung cancer care
Molecularly Guided Treatment Planning
Targeted TherapyTreatment selection based on the molecular characteristics of the tumour.
Molecular Diagnostics and Staging
DiagnosisMolecular profiling and staging review before treatment decisions.
Systemic Treatment for Advanced Lung Cancer
Medical OncologyTreatment planning and oversight for advanced and metastatic lung cancer.
Multidisciplinary Case Review
MultidisciplinaryCombined review of surgical, radiation and systemic treatment options.
Second Opinion Consultations
Second OpinionIndependent expert review of diagnosis and treatment plan.
Research & Publications
Clinical trial leadership and peer-reviewed contributions
Prof. Wu has authored and co-authored hundreds of peer-reviewed publications in leading international medical journals, including The New England Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology.
A more detailed publication list may be available on request through CancerFax.
Education & Training
Prof. Wu trained in China and Germany over a career beginning in the early 1980s.
Clinical Experience
Prof. Wu has spent his career at Guangdong Provincial People's Hospital and the Guangdong Lung Cancer Institute, where he has led lung cancer research and treatment for decades.
Languages & International
Prof. Wu's consultation languages include the following.
CancerFax can coordinate professional medical interpreter support for international patients.
CancerFax can coordinate professional medical interpreter support when required.
How CancerFax Helps You Access Dr. Yi-Long Wu
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Yi-Long Wu's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Yi-Long Wu's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Yi-Long Wu before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Yi-Long Wu's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Yi-Long Wu's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Yi-Long Wu's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Yi-Long Wu
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Wu, subject to hospital availability and case acceptance.
Prof. Wu focuses on lung cancer precision medicine, with particular expertise in non-small cell lung cancer driven by EGFR, ALK and ROS1 alterations. His work covers targeted therapy, adjuvant treatment after surgery, management of advanced and metastatic disease, and multidisciplinary treatment planning.
Submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps with the hospital or doctor, subject to availability.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, molecular testing results and treatment history. The final consultation format and availability depend on the doctor's institution.
Yes. Prof. Wu founded the Chinese Thoracic Oncology Group (CTONG) in 2007 and has contributed to landmark lung cancer trials including IPASS, AURA3, ADAURA and ARCHER 1050. CancerFax can help assess whether a patient may be eligible for relevant open trials, subject to institutional availability.
Connect with Yi-Long Wu Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.